Sorafeshield contains sorafenib 200 mg, an oral multikinase inhibitor used in the treatment of certain cancers. Sorafenib works by inhibiting multiple protein kinases involved in tumour-cell growth, proliferation and the formation of new blood vessels that can support tumour growth.
Sorafenib is used in approved clinical settings for certain patients with unresectable hepatocellular carcinoma, advanced renal cell carcinoma and differentiated thyroid carcinoma that is refractory to radioactive iodine treatment, depending on applicable product labeling and clinical guidelines.
Treatment should be initiated and monitored by an experienced oncology professional. Regular monitoring may include blood pressure, liver function, blood counts, electrolyte levels and other clinically appropriate parameters.
Contact Details
Website:
Email:
medicinesfromindia55@gmail.com
WhatsApp Number:
